Phio pharmaceuticals corp. (PHIO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Sep'11Jun'11
Revenues

0

0

0

0

21

0

57

58

23

-

0

0

-

0

0

9

10

0

0

0

34

-

-

-

-

-

-

-

53

-

57

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16

12

29

29

92

225

53

-

57

-

-

-

-

Operating expenses:
Research and development expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,017

1,021

1,690

Research and development employee stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

38

79

146

Research and development non-employee stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

99

26

-44

Research and development

1,218

1,023

1,042

1,146

1,089

944

838

1,183

1,361

1,204

1,490

1,329

1,347

1,307

1,464

1,339

1,305

1,723

1,734

1,361

2,107

1,562

1,459

1,183

1,476

1,438

1,229

1,213

13,771

1,136

1,214

6,947

1,154

1,126

1,792

Acquired in-process research and development

-

-

-

-

-

-

-

-

-

0

0

85

4,611

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

674

730

-

General and administrative expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

876

General and administrative employee stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

77

301

165

Common stock warrants issued for general and administrative expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10

5

General and administrative

1,138

1,646

1,071

913

1,078

790

711

774

901

802

986

1,100

1,123

1,032

752

885

950

899

770

804

873

758

766

850

843

1,110

934

977

676

615

539

716

751

1,041

1,046

Total operating expenses

2,356

2,669

2,113

2,059

2,167

1,734

1,549

1,957

2,262

2,006

2,476

2,514

7,081

2,339

2,216

2,224

2,255

2,622

2,504

2,165

2,980

2,320

2,225

2,033

2,319

2,548

2,163

2,190

14,447

1,751

1,753

7,663

1,905

-

2,838

Operating loss

-2,356

-2,669

-2,113

-2,059

-2,146

-1,734

-1,492

-1,899

-2,239

-1,991

-2,476

-2,514

-7,081

-2,339

-2,216

-2,215

-2,245

-2,622

-2,504

-2,165

-2,946

-2,306

-2,209

-2,021

-2,290

-2,519

-2,071

-1,965

-14,394

-1,711

-1,696

-7,663

-1,905

-2,167

-

Interest (expense) income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

0

4

4

7

6

8

1

1

2

4

5

6

-

10

4

-

-

-

-

-

-

-

Interest income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-1

-1

-6

-22

-

-

Interest income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

-

Interest income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

Other (expense) income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-1

7

-

-

-2

-

-

-1

10

-

-

2

0

-3

1

53

70

1

123

955

Total other income, net

5

9

19

24

27

7

-1

-2

0

-11

0

0

0

0

4

3

14

6

8

-1

1

-

3

15

-

-

-

-

-

-

-

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-2,002

-2,476

-2,514

-7,081

-2,339

-2,212

-2,212

-2,231

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for income taxes

-

-

-

-

-

-

-

-

-

0

0

0

-1,621

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-2,351

-2,660

-2,094

-2,035

-2,119

-1,727

-1,493

-1,901

-2,239

-2,002

-2,476

-2,514

-5,460

-2,339

-2,212

-2,212

-2,231

-2,616

-2,496

-2,166

-2,945

-2,304

-2,206

-2,006

-2,284

-2,508

-2,059

-1,961

-14,397

-1,711

-1,644

-7,599

-1,926

-2,043

-1,882

Accretion of beneficial conversion feature related to Series B Convertible Preferred Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

24

185

462

700

1,213

1,755

-

-

-

-

-

-

-

-

-

-

Series A and Series A-1 convertible preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,447

2,399

3,547

-

1,277

10,620

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,616

-2,496

-2,190

-3,130

-2,766

-2,906

-3,219

-4,039

-3,725

-3,506

-4,360

-17,944

-2,629

-2,921

-18,219

-1,926

-2,043

-1,882

Net loss per share: Basic and diluted

-1.33

-13.46

-0.08

-0.08

-5.71

-55.76

-0.34

-0.46

-0.90

-0.70

-1.05

-1.12

-2.65

-6.26

-3.36

-3.38

-3.41

0.10

-0.38

-0.50

-1.32

-7.18

-0.17

-0.23

-0.32

0.57

-0.30

-0.39

-2.76

-0.89

-0.56

-4.13

-0.04

-0.05

-0.05

Weighted average shares: basic and diluted

1,772

-48,163

25,409

24,226

371

-10,455

4,371

4,102

2,494

2,383

2,351

2,238

2,057

733

657

653

653

6,591

6,494

4,419

2,376

-37,580

17,494

14,015

12,616

11,761

11,630

11,168

6,496

-47,958,849

5,238

4,406

47,967,499

41,970

38,568